<DOC>
	<DOC>NCT01275625</DOC>
	<brief_summary>One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy and safety of this combination in a Russian population of patients.</brief_summary>
	<brief_title>Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Over 18 years of age. R5 HIV infection on screening tropism test. Viral load &gt;1,000 copies/mL. Never previously treated with antiHIV medicines. Previously treated with antiHIV medicines. Hepatitis B coinfection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>naive</keyword>
	<keyword>hiv</keyword>
	<keyword>zidovudine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>combivir</keyword>
	<keyword>Clade A</keyword>
</DOC>